INVIVO THERAPEU.
INVIVO THERAPEU.
Share · US46186M6057 · NVIV (LSSI)
Overview
No Price
n/a
1 day
-
1 week
-
1 month
-
3 months
-
6 months
-
Year to date
-
1 year
-
2 years
-
3 years
-
4 years
-
5 years
-
10 years
-
20 years
-
Max
-
Analyst Grade Summary
gauge-img
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell
0
3
0
0
0
Share Float & Liquidity
Free Float 99,73 %
Shares Float 3,1 M
Shares Outstanding 3,11 M
Company Profile for INVIVO THERAPEU. Share
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord to treat acute SCI. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.

Company Data

Name INVIVO THERAPEU.
Company InVivo Therapeutics Holdings Corporation
Symbol NVIV
Website https://www.invivotherapeutics.com
Primary Exchange LSSI Lang & Schwarz
ISIN US46186M6057
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Richard M. Toselli
Country United States of America
Currency EUR
Employees 0,0 T
Address One Kendall Square, 02139 Cambridge
IPO Date 2010-11-15

Ticker Symbols

Name Symbol
NASDAQ NVIV
More Shares
Investors who hold INVIVO THERAPEU. also have the following shares in their portfolio:
ISHARES CORE TOTAL USD BOND MARKET ETF
ISHARES CORE TOTAL USD BOND MARKET ETF ETF
Treasure Factory Co.,LTD.
Treasure Factory Co.,LTD. Share
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025